ERBB2 and breast cancer: In clinical practice, molecular breast cancer subtypes, i.e., luminal A, luminal B, HER2-positive, and TN, are usually derived using immunohistochemistry surrogates to inform on tumor aggressiveness, prognosis, and prediction, and are routinely used to guide recommendations for neo- and adjuvant systemic therapies [20,21].